PittsburghV1, PascalFrancis, Checkpoint, bibRecord, 002C82

Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma

Identifieur interne : 002C82 ( PascalFrancis/Checkpoint ); précédent : 002C81; suivant : 002C83

Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma

Auteurs : Eric Bouffet [Canada] ; Regina Jakacki [États-Unis] ; Stewart Goldman [États-Unis] ; Darren Hargrave [Royaume-Uni] ; Cynthia Hawkins [Canada] ; Manohar Shroff [Canada] ; Juliette Hukin [Canada, États-Unis] ; Ute Bartels [Canada] ; Nicholas Foreman [États-Unis] ; Stewart Kellie [Australie] ; Joanne Hilden [États-Unis] ; Michael Etzl [États-Unis] ; Beverly Wilson [Canada] ; Derek Stephens [Canada] ; Uri Tabori [Canada] ; Sylvain Baruchel [Canada]

Source :

Journal of clinical oncology [ 0732-183X ] ; 2012.

RBID : Pascal:12-0196668

Descripteurs français

Pascal (Inist)
- Essai clinique phase II, Traitement, Rythme administration, Vinblastine, Récidive, Résistance traitement, Bas grade, Enfant, Pédiatrie, Gliome, Cancérologie, Anticancéreux.
Wicri :
- topic : Enfant, Pédiatrie.

English descriptors

KwdEn :
- Administration schedule, Antineoplastic agent, Cancerology, Child, Glioma, Low grade, Pediatrics, Phase II trial, Relapse, Treatment, Treatment resistance, Vinblastine.

Abstract

Purpose To evaluate the efficacy of single-agent vinblastine in pediatric patients with recurrent or refractory low-grade glioma. Patients and Methods Patients were eligible if they had experienced previous treatment failure (chemotherapy and/or radiation) for incompletely resected or unresectable low-grade glioma (LGG). Vinblastine (6 mg/m²) was administered weekly for 1 year unless unacceptable toxicity or progression (confirmed on two consecutive imaging studies) occurred. Results Fifty-one patients (age range, 1.4 to 18.2 years; median age, 7.2 years) were prospectively enrolled onto this phase II study. Fifty patients had previously received at least one prior regimen of chemotherapy, and 10 patients had previously received radiation treatment. Fifty patients were evaluable for response; 18 patients (36%) had a complete, partial, or minor response, and 31 patients completed 1 year of treatment. At a median follow-up of 67 months, 23 patients had not experienced progression; three patients have died. Five-year overall survival was 93.2% ± 3.8%, and 5-year progression-free survival was 42.3% ± 7.2%. Toxicity was manageable and mostly hematologic, although a few patients needed transfusions. Conclusion Weekly vinblastine seems to be a reasonable alternative to radiation for pediatric patients with LGG who have experienced treatment failure with first-line chemotherapy. The 5-year progression-free survival observed in this phase II trial is comparable to results observed with first-line chemotherapy in chemotherapy-naive patients. The role of single-agent vinblastine and other vinca alkaloid in the management of pediatric LGGs deserves further investigation.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 004347
to stream PascalFrancis, to step Curation: 000B59

Links to Exploration step

Pascal:12-0196668

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma</title>
<author><name sortKey="Bouffet, Eric" sort="Bouffet, Eric" uniqKey="Bouffet E" first="Eric" last="Bouffet">Eric Bouffet</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Hospital for Sick Children, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Jakacki, Regina" sort="Jakacki, Regina" uniqKey="Jakacki R" first="Regina" last="Jakacki">Regina Jakacki</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Children's Hospital of Pittsburgh</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Children's Hospital of Pittsburgh</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Goldman, Stewart" sort="Goldman, Stewart" uniqKey="Goldman S" first="Stewart" last="Goldman">Stewart Goldman</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Children's Memorial Medical Center</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Children's Memorial Medical Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hargrave, Darren" sort="Hargrave, Darren" uniqKey="Hargrave D" first="Darren" last="Hargrave">Darren Hargrave</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>The Royal Marsden Hospital</s1>
<s2>Sutton</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>The Royal Marsden Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hawkins, Cynthia" sort="Hawkins, Cynthia" uniqKey="Hawkins C" first="Cynthia" last="Hawkins">Cynthia Hawkins</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Hospital for Sick Children, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Shroff, Manohar" sort="Shroff, Manohar" uniqKey="Shroff M" first="Manohar" last="Shroff">Manohar Shroff</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Hospital for Sick Children, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Hukin, Juliette" sort="Hukin, Juliette" uniqKey="Hukin J" first="Juliette" last="Hukin">Juliette Hukin</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>British Columbia Children's Hospital</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>British Columbia Children's Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Peyton Manning Children's Hospital at St Vincent</s1>
<s2>Indianapolis, IN</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Peyton Manning Children's Hospital at St Vincent</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bartels, Ute" sort="Bartels, Ute" uniqKey="Bartels U" first="Ute" last="Bartels">Ute Bartels</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Hospital for Sick Children, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Foreman, Nicholas" sort="Foreman, Nicholas" uniqKey="Foreman N" first="Nicholas" last="Foreman">Nicholas Foreman</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>The Children's Hospital</s1>
<s2>Denver, CO</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>The Children's Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kellie, Stewart" sort="Kellie, Stewart" uniqKey="Kellie S" first="Stewart" last="Kellie">Stewart Kellie</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>The Children's Hospital at Westmead</s1>
<s2>Westmead, New South Wales</s2>
<s3>AUS</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>The Children's Hospital at Westmead</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hilden, Joanne" sort="Hilden, Joanne" uniqKey="Hilden J" first="Joanne" last="Hilden">Joanne Hilden</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>The Children's Hospital at The Cleveland Clinic</s1>
<s2>Cleveland, OH</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>The Children's Hospital at The Cleveland Clinic</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Etzl, Michael" sort="Etzl, Michael" uniqKey="Etzl M" first="Michael" last="Etzl">Michael Etzl</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Phoenix Children's Hospital</s1>
<s2>Phoenix, AZ</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Phoenix Children's Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wilson, Beverly" sort="Wilson, Beverly" uniqKey="Wilson B" first="Beverly" last="Wilson">Beverly Wilson</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of Alberta Hospital</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of Alberta Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stephens, Derek" sort="Stephens, Derek" uniqKey="Stephens D" first="Derek" last="Stephens">Derek Stephens</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Hospital for Sick Children, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Tabori, Uri" sort="Tabori, Uri" uniqKey="Tabori U" first="Uri" last="Tabori">Uri Tabori</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Hospital for Sick Children, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Baruchel, Sylvain" sort="Baruchel, Sylvain" uniqKey="Baruchel S" first="Sylvain" last="Baruchel">Sylvain Baruchel</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Hospital for Sick Children, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">12-0196668</idno>
<date when="2012">2012</date>
<idno type="stanalyst">PASCAL 12-0196668 INIST</idno>
<idno type="RBID">Pascal:12-0196668</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">004347</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000B59</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">002C82</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">002C82</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma</title>
<author><name sortKey="Bouffet, Eric" sort="Bouffet, Eric" uniqKey="Bouffet E" first="Eric" last="Bouffet">Eric Bouffet</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Hospital for Sick Children, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Jakacki, Regina" sort="Jakacki, Regina" uniqKey="Jakacki R" first="Regina" last="Jakacki">Regina Jakacki</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Children's Hospital of Pittsburgh</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Children's Hospital of Pittsburgh</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Goldman, Stewart" sort="Goldman, Stewart" uniqKey="Goldman S" first="Stewart" last="Goldman">Stewart Goldman</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Children's Memorial Medical Center</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Children's Memorial Medical Center</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hargrave, Darren" sort="Hargrave, Darren" uniqKey="Hargrave D" first="Darren" last="Hargrave">Darren Hargrave</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>The Royal Marsden Hospital</s1>
<s2>Sutton</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<wicri:noRegion>The Royal Marsden Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hawkins, Cynthia" sort="Hawkins, Cynthia" uniqKey="Hawkins C" first="Cynthia" last="Hawkins">Cynthia Hawkins</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Hospital for Sick Children, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Shroff, Manohar" sort="Shroff, Manohar" uniqKey="Shroff M" first="Manohar" last="Shroff">Manohar Shroff</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Hospital for Sick Children, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Hukin, Juliette" sort="Hukin, Juliette" uniqKey="Hukin J" first="Juliette" last="Hukin">Juliette Hukin</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>British Columbia Children's Hospital</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>British Columbia Children's Hospital</wicri:noRegion>
</affiliation>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Peyton Manning Children's Hospital at St Vincent</s1>
<s2>Indianapolis, IN</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Peyton Manning Children's Hospital at St Vincent</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Bartels, Ute" sort="Bartels, Ute" uniqKey="Bartels U" first="Ute" last="Bartels">Ute Bartels</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Hospital for Sick Children, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Foreman, Nicholas" sort="Foreman, Nicholas" uniqKey="Foreman N" first="Nicholas" last="Foreman">Nicholas Foreman</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>The Children's Hospital</s1>
<s2>Denver, CO</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>The Children's Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Kellie, Stewart" sort="Kellie, Stewart" uniqKey="Kellie S" first="Stewart" last="Kellie">Stewart Kellie</name>
<affiliation wicri:level="1"><inist:fA14 i1="11"><s1>The Children's Hospital at Westmead</s1>
<s2>Westmead, New South Wales</s2>
<s3>AUS</s3>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Australie</country>
<wicri:noRegion>The Children's Hospital at Westmead</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Hilden, Joanne" sort="Hilden, Joanne" uniqKey="Hilden J" first="Joanne" last="Hilden">Joanne Hilden</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>The Children's Hospital at The Cleveland Clinic</s1>
<s2>Cleveland, OH</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>The Children's Hospital at The Cleveland Clinic</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Etzl, Michael" sort="Etzl, Michael" uniqKey="Etzl M" first="Michael" last="Etzl">Michael Etzl</name>
<affiliation wicri:level="1"><inist:fA14 i1="09"><s1>Phoenix Children's Hospital</s1>
<s2>Phoenix, AZ</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<wicri:noRegion>Phoenix Children's Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wilson, Beverly" sort="Wilson, Beverly" uniqKey="Wilson B" first="Beverly" last="Wilson">Beverly Wilson</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>University of Alberta Hospital</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<wicri:noRegion>University of Alberta Hospital</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stephens, Derek" sort="Stephens, Derek" uniqKey="Stephens D" first="Derek" last="Stephens">Derek Stephens</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Hospital for Sick Children, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Tabori, Uri" sort="Tabori, Uri" uniqKey="Tabori U" first="Uri" last="Tabori">Uri Tabori</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Hospital for Sick Children, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
<author><name sortKey="Baruchel, Sylvain" sort="Baruchel, Sylvain" uniqKey="Baruchel S" first="Sylvain" last="Baruchel">Sylvain Baruchel</name>
<affiliation wicri:level="4"><inist:fA14 i1="01"><s1>Hospital for Sick Children, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</inist:fA14>
<country>Canada</country>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
<orgName type="university">Université de Toronto</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
<imprint><date when="2012">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Journal of clinical oncology</title>
<title level="j" type="abbreviated">J. clin. oncol.</title>
<idno type="ISSN">0732-183X</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Administration schedule</term>
<term>Antineoplastic agent</term>
<term>Cancerology</term>
<term>Child</term>
<term>Glioma</term>
<term>Low grade</term>
<term>Pediatrics</term>
<term>Phase II trial</term>
<term>Relapse</term>
<term>Treatment</term>
<term>Treatment resistance</term>
<term>Vinblastine</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Essai clinique phase II</term>
<term>Traitement</term>
<term>Rythme administration</term>
<term>Vinblastine</term>
<term>Récidive</term>
<term>Résistance traitement</term>
<term>Bas grade</term>
<term>Enfant</term>
<term>Pédiatrie</term>
<term>Gliome</term>
<term>Cancérologie</term>
<term>Anticancéreux</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Enfant</term>
<term>Pédiatrie</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Purpose To evaluate the efficacy of single-agent vinblastine in pediatric patients with recurrent or refractory low-grade glioma. Patients and Methods Patients were eligible if they had experienced previous treatment failure (chemotherapy and/or radiation) for incompletely resected or unresectable low-grade glioma (LGG). Vinblastine (6 mg/m<sup>2</sup>
) was administered weekly for 1 year unless unacceptable toxicity or progression (confirmed on two consecutive imaging studies) occurred. Results Fifty-one patients (age range, 1.4 to 18.2 years; median age, 7.2 years) were prospectively enrolled onto this phase II study. Fifty patients had previously received at least one prior regimen of chemotherapy, and 10 patients had previously received radiation treatment. Fifty patients were evaluable for response; 18 patients (36%) had a complete, partial, or minor response, and 31 patients completed 1 year of treatment. At a median follow-up of 67 months, 23 patients had not experienced progression; three patients have died. Five-year overall survival was 93.2% ± 3.8%, and 5-year progression-free survival was 42.3% ± 7.2%. Toxicity was manageable and mostly hematologic, although a few patients needed transfusions. Conclusion Weekly vinblastine seems to be a reasonable alternative to radiation for pediatric patients with LGG who have experienced treatment failure with first-line chemotherapy. The 5-year progression-free survival observed in this phase II trial is comparable to results observed with first-line chemotherapy in chemotherapy-naive patients. The role of single-agent vinblastine and other vinca alkaloid in the management of pediatric LGGs deserves further investigation.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0732-183X</s0>
</fA01>
<fA03 i2="1"><s0>J. clin. oncol.</s0>
</fA03>
<fA05><s2>30</s2>
</fA05>
<fA06><s2>12</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>BOUFFET (Eric)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>JAKACKI (Regina)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>GOLDMAN (Stewart)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HARGRAVE (Darren)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>HAWKINS (Cynthia)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SHROFF (Manohar)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>HUKIN (Juliette)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>BARTELS (Ute)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>FOREMAN (Nicholas)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>KELLIE (Stewart)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>HILDEN (Joanne)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>ETZL (Michael)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>WILSON (Beverly)</s1>
</fA11>
<fA11 i1="14" i2="1"><s1>STEPHENS (Derek)</s1>
</fA11>
<fA11 i1="15" i2="1"><s1>TABORI (Uri)</s1>
</fA11>
<fA11 i1="16" i2="1"><s1>BARUCHEL (Sylvain)</s1>
</fA11>
<fA14 i1="01"><s1>Hospital for Sick Children, University of Toronto</s1>
<s2>Toronto, Ontario</s2>
<s3>CAN</s3>
<sZ>1 aut.</sZ>
<sZ>5 aut.</sZ>
<sZ>6 aut.</sZ>
<sZ>8 aut.</sZ>
<sZ>14 aut.</sZ>
<sZ>15 aut.</sZ>
<sZ>16 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>British Columbia Children's Hospital</s1>
<s2>Vancouver, British Columbia</s2>
<s3>CAN</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>University of Alberta Hospital</s1>
<s2>Edmonton, Alberta</s2>
<s3>CAN</s3>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Children's Hospital of Pittsburgh</s1>
<s2>Pittsburgh, PA</s2>
<s3>USA</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Children's Memorial Medical Center</s1>
<s2>Chicago, IL</s2>
<s3>USA</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>The Children's Hospital</s1>
<s2>Denver, CO</s2>
<s3>USA</s3>
<sZ>9 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Peyton Manning Children's Hospital at St Vincent</s1>
<s2>Indianapolis, IN</s2>
<s3>USA</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>The Children's Hospital at The Cleveland Clinic</s1>
<s2>Cleveland, OH</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Phoenix Children's Hospital</s1>
<s2>Phoenix, AZ</s2>
<s3>USA</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>The Royal Marsden Hospital</s1>
<s2>Sutton</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="11"><s1>The Children's Hospital at Westmead</s1>
<s2>Westmead, New South Wales</s2>
<s3>AUS</s3>
<sZ>10 aut.</sZ>
</fA14>
<fA20><s1>1358-1363</s1>
</fA20>
<fA21><s1>2012</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20094</s2>
<s5>354000509696420200</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2012 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>33 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>12-0196668</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Journal of clinical oncology</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Purpose To evaluate the efficacy of single-agent vinblastine in pediatric patients with recurrent or refractory low-grade glioma. Patients and Methods Patients were eligible if they had experienced previous treatment failure (chemotherapy and/or radiation) for incompletely resected or unresectable low-grade glioma (LGG). Vinblastine (6 mg/m<sup>2</sup>
) was administered weekly for 1 year unless unacceptable toxicity or progression (confirmed on two consecutive imaging studies) occurred. Results Fifty-one patients (age range, 1.4 to 18.2 years; median age, 7.2 years) were prospectively enrolled onto this phase II study. Fifty patients had previously received at least one prior regimen of chemotherapy, and 10 patients had previously received radiation treatment. Fifty patients were evaluable for response; 18 patients (36%) had a complete, partial, or minor response, and 31 patients completed 1 year of treatment. At a median follow-up of 67 months, 23 patients had not experienced progression; three patients have died. Five-year overall survival was 93.2% ± 3.8%, and 5-year progression-free survival was 42.3% ± 7.2%. Toxicity was manageable and mostly hematologic, although a few patients needed transfusions. Conclusion Weekly vinblastine seems to be a reasonable alternative to radiation for pediatric patients with LGG who have experienced treatment failure with first-line chemotherapy. The 5-year progression-free survival observed in this phase II trial is comparable to results observed with first-line chemotherapy in chemotherapy-naive patients. The role of single-agent vinblastine and other vinca alkaloid in the management of pediatric LGGs deserves further investigation.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B04</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17E</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Essai clinique phase II</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Phase II trial</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Ensayo clínico fase II</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Traitement</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Treatment</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Tratamiento</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Rythme administration</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Administration schedule</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Ritmo administración</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Vinblastine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Vinblastine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Vinblastina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Récidive</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Relapse</s0>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Recaida</s0>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Résistance traitement</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Treatment resistance</s0>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Resistencia tratamiento</s0>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Bas grade</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Low grade</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Bajo grado</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Enfant</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Child</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Niño</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Pédiatrie</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Pediatrics</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Pediatría</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Gliome</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Glioma</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Glioma</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Cancérologie</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Cancerology</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Cancerología</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Anticancéreux</s0>
<s5>25</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Antineoplastic agent</s0>
<s5>25</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Anticanceroso</s0>
<s5>25</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Homme</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Human</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Hombre</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Alcaloïde</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Alkaloid</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Alcaloide</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Antimitotique</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Antimitotic</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Antimitótico</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Tumeur</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Tumor</s0>
<s5>41</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Tumor</s0>
<s5>41</s5>
</fC07>
<fN21><s1>149</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Australie</li>
<li>Canada</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Ontario</li>
</region>
<settlement><li>Toronto</li>
</settlement>
<orgName><li>Université de Toronto</li>
</orgName>
</list>
<tree><country name="Canada"><region name="Ontario"><name sortKey="Bouffet, Eric" sort="Bouffet, Eric" uniqKey="Bouffet E" first="Eric" last="Bouffet">Eric Bouffet</name>
</region>
<name sortKey="Bartels, Ute" sort="Bartels, Ute" uniqKey="Bartels U" first="Ute" last="Bartels">Ute Bartels</name>
<name sortKey="Baruchel, Sylvain" sort="Baruchel, Sylvain" uniqKey="Baruchel S" first="Sylvain" last="Baruchel">Sylvain Baruchel</name>
<name sortKey="Hawkins, Cynthia" sort="Hawkins, Cynthia" uniqKey="Hawkins C" first="Cynthia" last="Hawkins">Cynthia Hawkins</name>
<name sortKey="Hukin, Juliette" sort="Hukin, Juliette" uniqKey="Hukin J" first="Juliette" last="Hukin">Juliette Hukin</name>
<name sortKey="Shroff, Manohar" sort="Shroff, Manohar" uniqKey="Shroff M" first="Manohar" last="Shroff">Manohar Shroff</name>
<name sortKey="Stephens, Derek" sort="Stephens, Derek" uniqKey="Stephens D" first="Derek" last="Stephens">Derek Stephens</name>
<name sortKey="Tabori, Uri" sort="Tabori, Uri" uniqKey="Tabori U" first="Uri" last="Tabori">Uri Tabori</name>
<name sortKey="Wilson, Beverly" sort="Wilson, Beverly" uniqKey="Wilson B" first="Beverly" last="Wilson">Beverly Wilson</name>
</country>
<country name="États-Unis"><noRegion><name sortKey="Jakacki, Regina" sort="Jakacki, Regina" uniqKey="Jakacki R" first="Regina" last="Jakacki">Regina Jakacki</name>
</noRegion>
<name sortKey="Etzl, Michael" sort="Etzl, Michael" uniqKey="Etzl M" first="Michael" last="Etzl">Michael Etzl</name>
<name sortKey="Foreman, Nicholas" sort="Foreman, Nicholas" uniqKey="Foreman N" first="Nicholas" last="Foreman">Nicholas Foreman</name>
<name sortKey="Goldman, Stewart" sort="Goldman, Stewart" uniqKey="Goldman S" first="Stewart" last="Goldman">Stewart Goldman</name>
<name sortKey="Hilden, Joanne" sort="Hilden, Joanne" uniqKey="Hilden J" first="Joanne" last="Hilden">Joanne Hilden</name>
<name sortKey="Hukin, Juliette" sort="Hukin, Juliette" uniqKey="Hukin J" first="Juliette" last="Hukin">Juliette Hukin</name>
</country>
<country name="Royaume-Uni"><noRegion><name sortKey="Hargrave, Darren" sort="Hargrave, Darren" uniqKey="Hargrave D" first="Darren" last="Hargrave">Darren Hargrave</name>
</noRegion>
</country>
<country name="Australie"><noRegion><name sortKey="Kellie, Stewart" sort="Kellie, Stewart" uniqKey="Kellie S" first="Stewart" last="Kellie">Stewart Kellie</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Amérique/explor/PittsburghV1/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002C82 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 002C82 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Amérique
   |area=    PittsburghV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:12-0196668
   |texte=   Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma
}}

This area was generated with Dilib version V0.6.38.
Data generation: Fri Jun 18 17:37:45 2021. Site generation: Fri Jun 18 18:15:47 2021

	Serveur d'exploration sur Pittsburgh
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur Pittsburgh

Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma

Phase II Study of Weekly Vinblastine in Recurrent or Refractory Pediatric Low-Grade Glioma

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri